Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    FDA Approves Quadrivalent Flu Shot for Adults

    By Global Biodefense StaffDecember 15, 2014
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Sanofi’s Fluzone Intradermal Quadrivalent vaccine.

    Fluzone Intradermal vaccine, which has been available in trivalent formulation for three years, is now available in a quadrivalent formulation to help protect against four strains of influenza virus. The shot is indicated for adults 18 through 64 years of age for active immunization for the prevention of influenza caused by influenza A subtype viruses and type B viruses contained in the vaccine.

    “Influenza B is a common cause of influenza-related morbidity and mortality across all age groups,” said David P. Greenberg, M.D., Vice President, Scientific & Medical Affairs, and Chief Medical Officer, Sanofi Pasteur US. “Fluzone Intradermal Quadrivalent vaccine will offer another influenza vaccination option for health care providers and their adult patients with broad coverage against influenza viruses that may be predominant, coupled with the efficiency of using the intradermal microinjection system.”

    Traditional three-strain—or trivalent—influenza vaccines contain two strains of influenza A and one strain of influenza B. Influenza B represents 20 to 25 percent of circulating influenza strains and is associated with substantial morbidity and mortality.

    Two distinct families of influenza B (Victoria and Yamagata) have been co-circulating worldwide for over a decade, making it difficult to predict which will predominate during a given season. According to the Centers for Disease Control and Prevention (CDC), in six of the past 13 influenza seasons (2001-2013), the B strain included in the vaccine did not match the predominant B strain in circulation.

    “Fluzone Intradermal Quadrivalent was developed to help address this frequent B-strain mismatch and broaden coverage against influenza by incorporating a B strain from each lineage,” stated Sanofi.

    Influenza Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleTeaming Up with the U.S. Army to Treat Hantavirus
    Next Article MERS-CoV Unlikely to Reach Epidemic Status

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.